U.S. FDA clears Investigational New Drug application for THB335
Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25
Read more at globenewswire.comThird Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
THIRD HARMONIC BIO INC
NASDAQ:THRD (2/11/2025, 8:00:01 PM)
After market: 3.26 +0.01 (+0.31%)3.25
-1.4 (-30.11%)
THRD Latest News and Analysis
11 hours ago - ChartmillTuesday's session: top gainers and losersIntrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
16 hours ago - ChartmillTuesday's session: gap up and gap down stocksLet's have a look at the gap up and gap down stocks in today's session.
18 hours ago - ChartmillWhich stocks are moving before the opening bell on Tuesday?As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
